Ignite Creation Date:
2025-12-25 @ 12:00 AM
Ignite Modification Date:
2026-06-25 @ 1:01 AM
Study NCT ID:
NCT05039658
Status:
UNKNOWN
Last Update Posted:
2021-09-09
First Post:
2021-09-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)
Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | DLBCL | View |
Keywords: